SIMCERE PHARMAC. GRP LTD (S2P) - Net Assets
Based on the latest financial reports, SIMCERE PHARMAC. GRP LTD (S2P) has net assets worth €9.41 Billion EUR (≈ $11.01 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.73 Billion ≈ $17.22 Billion USD) and total liabilities (€5.31 Billion ≈ $6.21 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore SIMCERE PHARMAC. GRP LTD cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €9.41 Billion |
| % of Total Assets | 63.93% |
| Annual Growth Rate | 9.86% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13.82 |
SIMCERE PHARMAC. GRP LTD - Net Assets Trend (2021–2025)
This chart illustrates how SIMCERE PHARMAC. GRP LTD's net assets have evolved over time, based on quarterly financial data. Also explore total assets of SIMCERE PHARMAC. GRP LTD for the complete picture of this company's asset base.
Annual Net Assets for SIMCERE PHARMAC. GRP LTD (2021–2025)
The table below shows the annual net assets of SIMCERE PHARMAC. GRP LTD from 2021 to 2025. For live valuation and market cap data, see SIMCERE PHARMAC. GRP LTD (S2P) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €9.41 Billion ≈ $11.01 Billion |
+33.20% |
| 2024-12-31 | €7.07 Billion ≈ $8.26 Billion |
-2.14% |
| 2023-12-31 | €7.22 Billion ≈ $8.44 Billion |
+1.05% |
| 2022-12-31 | €7.15 Billion ≈ $8.36 Billion |
+10.60% |
| 2021-12-31 | €6.46 Billion ≈ $7.56 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SIMCERE PHARMAC. GRP LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €9.41 Billion | 100.00% |
| Total Equity | €9.41 Billion | 100.00% |
SIMCERE PHARMAC. GRP LTD Competitors by Market Cap
The table below lists competitors of SIMCERE PHARMAC. GRP LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fonciere Lyonnaise
PA:FLY
|
$3.17 Billion |
|
Holy Stone Enterprise Co Ltd
TW:3026
|
$3.18 Billion |
|
Paramount Resources Ltd.
TO:POU
|
$3.18 Billion |
|
USA Compression Partners LP
NYSE:USAC
|
$3.18 Billion |
|
Varonis Systems
NASDAQ:VRNS
|
$3.17 Billion |
|
Mandatum Oyj
HE:MANTA
|
$3.17 Billion |
|
Puig Brands SA
NYSE:PUGBY
|
$3.17 Billion |
|
Huaxi Securities Co Ltd Class A
SHE:002926
|
$3.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SIMCERE PHARMAC. GRP LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,068,115,000 to 9,407,866,000, a change of 2,339,751,000 (33.1%).
- Net income of 1,344,008,000 contributed positively to equity growth.
- Dividend payments of 390,746,000 reduced retained earnings.
- Share repurchases of 74,302,000 reduced equity.
- New share issuances of 1,427,070,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.34 Billion | +14.29% |
| Dividends Paid | €390.75 Million | -4.15% |
| Share Repurchases | €74.30 Million | -0.79% |
| Share Issuances | €1.43 Billion | +15.17% |
| Other Changes | €33.72 Million | +0.36% |
| Total Change | €- | 33.10% |
Book Value vs Market Value Analysis
This analysis compares SIMCERE PHARMAC. GRP LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.45x to 0.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.45 | €1.09 | x |
| 2022-12-31 | €2.68 | €1.09 | x |
| 2023-12-31 | €2.76 | €1.09 | x |
| 2024-12-31 | €2.80 | €1.09 | x |
| 2025-12-31 | €3.63 | €1.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SIMCERE PHARMAC. GRP LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.29%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.38%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.57x
- Recent ROE (14.29%) is above the historical average (14.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 23.41% | 30.14% | 0.49x | 1.58x | €863.40 Million |
| 2022 | 13.05% | 14.72% | 0.59x | 1.51x | €217.70 Million |
| 2023 | 9.90% | 10.82% | 0.61x | 1.50x | €-7.51 Million |
| 2024 | 10.21% | 10.88% | 0.58x | 1.63x | €15.19 Million |
| 2025 | 14.29% | 17.38% | 0.53x | 1.57x | €403.22 Million |
Industry Comparison
This section compares SIMCERE PHARMAC. GRP LTD's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,058,012,174
- Average return on equity (ROE) among peers: -98.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SIMCERE PHARMAC. GRP LTD (S2P) | €9.41 Billion | 23.41% | 0.56x | $3.17 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.19 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $29.16 Million | -49.27% | 0.13x | $13.93 Million |
| EQL PHARMA AB (7JK) | $221.03 Million | 19.51% | 2.66x | $80.44 Million |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more